CORAL GABLES, Fla., June 30, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr.Steven Miller, Catalyst’s Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer,Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.